Literature DB >> 9531372

Does delay in breast irradiation following conservative breast surgery in node-negative breast cancer patients have an impact on risk of recurrence?

O Vujovic1, F Perera, A R Dar, L Stitt, E Yu, S M Voruganti, P T Truong.   

Abstract

PURPOSE: This retrospective review was conducted to determine if delay in the start of radiotherapy after definitive breast surgery had any detrimental effect on local recurrence or disease-free survival in node-negative breast cancer patients. METHODS AND MATERIALS: A total of 568 patients with T1-T2, N0 breast cancer were treated with breast-conserving surgery and breast irradiation, without adjuvant systemic therapy between January 1, 1985 and December 31, 1992, at the London Regional Cancer Centre. Adjuvant breast irradiation consisted either of 50 Gy in 25 fractions or 40 Gy in 15 or 16 fractions, followed by a boost of 10 Gy or 12.5 Gy to the lumpectomy site. The time intervals from definitive breast surgery to breast irradiation used for analysis were 0-8 weeks (201 patients), > 8-12 weeks (235 patients), > 1216 weeks (91 patients), and > 16 weeks (41 patients). The time intervals of 0-12 weeks (436 patients) and > 12 weeks (132 patients) were also analyzed. Kaplan-Meier estimates of time to local recurrence and disease-free survival rates were calculated. The association between surgery-radiotherapy interval, age (< or = 40, > 40 years), tumor size (< or = 2, > 2cm), Scharf-Bloom-Richardson (SBR) grade, resection margins, lymphatic vessel invasion, extensive intraductal component, and local recurrence and disease-free survival were investigated using Cox regression techniques.
RESULTS: Median follow-up was 63.5 months. Patients in all 4 time intervals were similar in terms of age and pathologic features. There was no statistically significant difference between the 4 groups in local recurrence or disease-free survival with surgery-radiotherapy interval (p = 0.189 and p = 0.413, respectively). The 5-year freedom from local relapse was 95.4%. The crude local recurrence rate was 6.9% (7.8% for 436 patients treated within 12 weeks (median follow-up 67 months) and 3.8% for 132 patients treated > 12 weeks from surgery (median follow-up 52 months). In a stepwise multivariable Cox regression model for disease-free survival, allowing for entry of known risk factors, tumour size (p < 0.001), grade (p < 0.001), and age (p = 0.048) entered the model, but the surgery-radiotherapy interval did not enter the model.
CONCLUSION: This retrospective study suggests that delay in start of breast irradiation beyond 12 and up to 16 weeks does not increase the risk of recurrence in node-negative breast cancer patients. The certainty of these results are limited by the retrospective nature of this analysis and the lack of information concerning the late local failure rate.

Entities:  

Mesh:

Year:  1998        PMID: 9531372     DOI: 10.1016/s0360-3016(97)00922-x

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  17 in total

1.  Timing of radiotherapy and outcome in patients receiving adjuvant endocrine therapy.

Authors:  Per Karlsson; Bernard F Cole; Marco Colleoni; Mario Roncadin; Boon H Chua; Elizabeth Murray; Karen N Price; Monica Castiglione-Gertsch; Aron Goldhirsch; Günther Gruber
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-08-21       Impact factor: 7.038

2.  Delays in primary surgical treatment are not associated with significant tumor size progression in breast cancer patients.

Authors:  Jamie L Wagner; Carla L Warneke; Elizabeth A Mittendorf; Isabelle Bedrosian; Gildy V Babiera; Henry M Kuerer; Kelly K Hunt; Wei Yang; Aysegul A Sahin; Funda Meric-Bernstam
Journal:  Ann Surg       Date:  2011-07       Impact factor: 12.969

3.  Breast Cancer OncoGuia.

Authors:  Paula Manchon; Josep M Borràs; Tàrsila Ferro; Josep Alfons Espinàs
Journal:  Clin Transl Oncol       Date:  2010-02       Impact factor: 3.405

4.  Timing of radiotherapy following breast-conserving surgery: outcome of 1393 patients at a single institution.

Authors:  S Corradini; O M Niemoeller; M Niyazi; F Manapov; M Haerting; N Harbeck; C Belka; S Kahlert
Journal:  Strahlenther Onkol       Date:  2014-02-07       Impact factor: 3.621

5.  The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma.

Authors:  Seunggu J Han; W Caleb Rutledge; Annette M Molinaro; Susan M Chang; Jennifer L Clarke; Michael D Prados; Jennie W Taylor; Mitchel S Berger; Nicholas A Butowski
Journal:  Neurosurgery       Date:  2015-08       Impact factor: 4.654

Review 6.  Impact of Timing of Concurrent Chemoradiation for Newly Diagnosed Glioblastoma: A Critical Review of Current Evidence.

Authors:  Seunggu J Han; Dario J Englot; Harjus Birk; Annette M Molinaro; Susan M Chang; Jennifer L Clarke; Michael D Prados; Jennie W Taylor; Mitchel S Berger; Nicholas A Butowski
Journal:  Neurosurgery       Date:  2015-08       Impact factor: 4.654

Review 7.  [Delays and treatment interruptions: difficulties in administering radiotherapy in an ideal time-period].

Authors:  Carmen González San Segundo; Felipe A Calvo Manuel; Juan Antonio Santos Miranda
Journal:  Clin Transl Oncol       Date:  2005-03       Impact factor: 3.405

8.  Anthracycline and concurrent radiotherapy as adjuvant treatment of operable breast cancer: a retrospective cohort study in a single institution.

Authors:  Nabil Ismaili; Sanaa Elmajjaoui; Issam Lalya; Lamia Boulaamane; Rhizlane Belbaraka; Halima Abahssain; Rachi Aassab; Noureddine Benjaafar; Brahim El Khalil El Guddari; Omar El Mesbahi; Yassir Sbitti; Mohammed Ismaili; Hassan Errihani
Journal:  BMC Res Notes       Date:  2010-10-04

9.  Short delay in initiation of radiotherapy may not affect outcome of patients with glioblastoma: a secondary analysis from the radiation therapy oncology group database.

Authors:  Deborah T Blumenthal; Minhee Won; Minesh P Mehta; Walter J Curran; Luis Souhami; Jeff M Michalski; C Leland Rogers; Benjamin W Corn
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

10.  Radiation treatment waiting times for breast cancer patients in Manitoba, 2001 and 2005.

Authors:  A L Cooke; R Appell; K Suderman; K Fradette; S Latosinsky
Journal:  Curr Oncol       Date:  2009-09       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.